HRP20090551T1 - Makrolidni konjugati s protuupalnom aktivnošću - Google Patents
Makrolidni konjugati s protuupalnom aktivnošću Download PDFInfo
- Publication number
- HRP20090551T1 HRP20090551T1 HR20090551T HRP20090551T HRP20090551T1 HR P20090551 T1 HRP20090551 T1 HR P20090551T1 HR 20090551 T HR20090551 T HR 20090551T HR P20090551 T HRP20090551 T HR P20090551T HR P20090551 T1 HRP20090551 T1 HR P20090551T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- solvate
- pharmaceutically acceptable
- acceptable salt
- acid
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 49
- 150000003839 salts Chemical class 0.000 claims abstract 32
- 239000012453 solvate Substances 0.000 claims abstract 32
- -1 cyano, amino Chemical group 0.000 claims abstract 31
- 125000003118 aryl group Chemical group 0.000 claims abstract 17
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract 11
- 125000001072 heteroaryl group Chemical class 0.000 claims abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 239000001257 hydrogen Substances 0.000 claims abstract 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical class 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 6
- 125000001424 substituent group Chemical group 0.000 claims abstract 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 5
- 230000003637 steroidlike Effects 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 4
- 125000001589 carboacyl group Chemical group 0.000 claims abstract 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 4
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract 3
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 3
- 229930195733 hydrocarbon Natural products 0.000 claims abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 3
- 150000003431 steroids Chemical class 0.000 claims abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002252 acyl group Chemical group 0.000 claims abstract 2
- 125000004442 acylamino group Chemical group 0.000 claims abstract 2
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims abstract 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims abstract 2
- 125000003435 aroyl group Chemical group 0.000 claims abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 2
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 claims abstract 2
- 125000005110 aryl thio group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000004122 cyclic group Chemical group 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims abstract 2
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 239000011593 sulfur Substances 0.000 claims abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 6
- 229960001680 ibuprofen Drugs 0.000 claims 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 230000004968 inflammatory condition Effects 0.000 claims 5
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 229960000905 indomethacin Drugs 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 229960005489 paracetamol Drugs 0.000 claims 4
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 claims 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229960004369 flufenamic acid Drugs 0.000 claims 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 3
- 229960000588 flunixin Drugs 0.000 claims 3
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims 3
- 229960000278 theophylline Drugs 0.000 claims 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims 2
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 claims 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 2
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 claims 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims 2
- 125000006091 1,3-dioxolane group Chemical group 0.000 claims 2
- XVDXNSRMHBAVAX-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-propan-2-ylbenzo[e]benzimidazole Chemical compound C1=CC(OC)=CC=C1C(N1C(C)C)=NC2=C1C=CC1=CC=CC=C21 XVDXNSRMHBAVAX-UHFFFAOYSA-N 0.000 claims 2
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 claims 2
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 claims 2
- KNKRHSVKIORZQB-UHFFFAOYSA-N 4-bromo-2-(hydroxymethyl)phenol Chemical compound OCC1=CC(Br)=CC=C1O KNKRHSVKIORZQB-UHFFFAOYSA-N 0.000 claims 2
- DJZRSPASHYGCDS-UHFFFAOYSA-N 5-(2-aminoacetyl)-2-hydroxybenzoic acid Chemical compound NCC(=O)C1=CC=C(O)C(C(O)=O)=C1 DJZRSPASHYGCDS-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 2
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims 2
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 2
- DJEIHHYCDCTAAH-UHFFFAOYSA-N Mofezolac (TN) Chemical compound C1=CC(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1 DJEIHHYCDCTAAH-UHFFFAOYSA-N 0.000 claims 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 claims 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 2
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 claims 2
- 229960004420 aceclofenac Drugs 0.000 claims 2
- 229960004892 acemetacin Drugs 0.000 claims 2
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims 2
- 229950007008 acetaminosalol Drugs 0.000 claims 2
- TWIIVLKQFJBFPW-UHFFFAOYSA-N acetaminosalol Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1O TWIIVLKQFJBFPW-UHFFFAOYSA-N 0.000 claims 2
- OGWGWBWZZQJMNO-UHFFFAOYSA-N acetic acid;5-bromo-2-hydroxybenzoic acid Chemical compound CC(O)=O.OC(=O)C1=CC(Br)=CC=C1O OGWGWBWZZQJMNO-UHFFFAOYSA-N 0.000 claims 2
- 229960005142 alclofenac Drugs 0.000 claims 2
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 claims 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims 2
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 claims 2
- 229950008930 amfenac Drugs 0.000 claims 2
- LSNWBKACGXCGAJ-UHFFFAOYSA-N ampiroxicam Chemical compound CN1S(=O)(=O)C2=CC=CC=C2C(OC(C)OC(=O)OCC)=C1C(=O)NC1=CC=CC=N1 LSNWBKACGXCGAJ-UHFFFAOYSA-N 0.000 claims 2
- 229950011249 ampiroxicam Drugs 0.000 claims 2
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 claims 2
- 229960002512 anileridine Drugs 0.000 claims 2
- 229960005430 benoxaprofen Drugs 0.000 claims 2
- REHLODZXMGOGQP-UHFFFAOYSA-N bermoprofen Chemical compound C1C(=O)C2=CC(C(C(O)=O)C)=CC=C2OC2=CC=C(C)C=C21 REHLODZXMGOGQP-UHFFFAOYSA-N 0.000 claims 2
- 229950007517 bermoprofen Drugs 0.000 claims 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims 2
- 229960003655 bromfenac Drugs 0.000 claims 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 claims 2
- 229950005608 bucloxic acid Drugs 0.000 claims 2
- UULSXYSSHHRCQK-UHFFFAOYSA-N butibufen Chemical compound CCC(C(O)=O)C1=CC=C(CC(C)C)C=C1 UULSXYSSHHRCQK-UHFFFAOYSA-N 0.000 claims 2
- 229960002973 butibufen Drugs 0.000 claims 2
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims 2
- 229960003184 carprofen Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- NKPPORKKCMYYTO-DHZHZOJOSA-N cinmetacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)\C=C\C1=CC=CC=C1 NKPPORKKCMYYTO-DHZHZOJOSA-N 0.000 claims 2
- 229950011171 cinmetacin Drugs 0.000 claims 2
- 229950010886 clidanac Drugs 0.000 claims 2
- 229940109248 cromoglycate Drugs 0.000 claims 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 2
- 229960001193 diclofenac sodium Drugs 0.000 claims 2
- 229960000616 diflunisal Drugs 0.000 claims 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229960005067 ditazole Drugs 0.000 claims 2
- UUCMDZWCRNZCOY-UHFFFAOYSA-N ditazole Chemical compound O1C(N(CCO)CCO)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UUCMDZWCRNZCOY-UHFFFAOYSA-N 0.000 claims 2
- 229960001850 droxicam Drugs 0.000 claims 2
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 claims 2
- 229950010996 enfenamic acid Drugs 0.000 claims 2
- HLNLBEFKHHCAMV-UHFFFAOYSA-N enfenamic acid Chemical compound OC(=O)C1=CC=CC=C1NCCC1=CC=CC=C1 HLNLBEFKHHCAMV-UHFFFAOYSA-N 0.000 claims 2
- 229960005293 etodolac Drugs 0.000 claims 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 2
- 229960001493 etofenamate Drugs 0.000 claims 2
- 229960000192 felbinac Drugs 0.000 claims 2
- 229960001395 fenbufen Drugs 0.000 claims 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims 2
- 229950005416 fendosal Drugs 0.000 claims 2
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 claims 2
- 229960001419 fenoprofen Drugs 0.000 claims 2
- 229960002679 fentiazac Drugs 0.000 claims 2
- 229950008205 fepradinol Drugs 0.000 claims 2
- PVOOBRUZWPQOER-UHFFFAOYSA-N fepradinol Chemical compound OCC(C)(C)NCC(O)C1=CC=CC=C1 PVOOBRUZWPQOER-UHFFFAOYSA-N 0.000 claims 2
- 229960001321 flunoxaprofen Drugs 0.000 claims 2
- ARPYQKTVRGFPIS-VIFPVBQESA-N flunoxaprofen Chemical compound N=1C2=CC([C@@H](C(O)=O)C)=CC=C2OC=1C1=CC=C(F)C=C1 ARPYQKTVRGFPIS-VIFPVBQESA-N 0.000 claims 2
- 229960002390 flurbiprofen Drugs 0.000 claims 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 2
- 229960002389 glycol salicylate Drugs 0.000 claims 2
- 229960004187 indoprofen Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- LZRDDINFIHUVCX-UHFFFAOYSA-N isofezolac Chemical compound OC(=O)CC1=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LZRDDINFIHUVCX-UHFFFAOYSA-N 0.000 claims 2
- 229950004425 isofezolac Drugs 0.000 claims 2
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 claims 2
- 229950002252 isoxicam Drugs 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 229960004752 ketorolac Drugs 0.000 claims 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 2
- 229960002202 lornoxicam Drugs 0.000 claims 2
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims 2
- 229960002373 loxoprofen Drugs 0.000 claims 2
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims 2
- JVGUNCHERKJFCM-UHFFFAOYSA-N mabuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 claims 2
- 229950001846 mabuprofen Drugs 0.000 claims 2
- 229960001929 meloxicam Drugs 0.000 claims 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 2
- 229960004963 mesalazine Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- LMINNBXUMGNKMM-UHFFFAOYSA-N metiazinic acid Chemical compound C1=C(CC(O)=O)C=C2N(C)C3=CC=CC=C3SC2=C1 LMINNBXUMGNKMM-UHFFFAOYSA-N 0.000 claims 2
- 229950005798 metiazinic acid Drugs 0.000 claims 2
- 229960000429 mofezolac Drugs 0.000 claims 2
- 229960005127 montelukast Drugs 0.000 claims 2
- 229960004270 nabumetone Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 229960000916 niflumic acid Drugs 0.000 claims 2
- 229960000965 nimesulide Drugs 0.000 claims 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 2
- 229960005113 oxaceprol Drugs 0.000 claims 2
- 229960002739 oxaprozin Drugs 0.000 claims 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 2
- 229960000649 oxyphenbutazone Drugs 0.000 claims 2
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 claims 2
- DXHYQIJBUNRPJT-UHFFFAOYSA-N parsalmide Chemical compound CCCCNC(=O)C1=CC(N)=CC=C1OCC#C DXHYQIJBUNRPJT-UHFFFAOYSA-N 0.000 claims 2
- XKFIQZCHJUUSBA-UHFFFAOYSA-N perisoxal Chemical compound C1=C(C=2C=CC=CC=2)ON=C1C(O)CN1CCCCC1 XKFIQZCHJUUSBA-UHFFFAOYSA-N 0.000 claims 2
- 229950005491 perisoxal Drugs 0.000 claims 2
- 229950009058 phenyl acetylsalicylate Drugs 0.000 claims 2
- PSBAIJVSCTZDDB-UHFFFAOYSA-N phenyl acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 PSBAIJVSCTZDDB-UHFFFAOYSA-N 0.000 claims 2
- 229960000969 phenyl salicylate Drugs 0.000 claims 2
- 229960002895 phenylbutazone Drugs 0.000 claims 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 2
- 229960002702 piroxicam Drugs 0.000 claims 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
- 229960003101 pranoprofen Drugs 0.000 claims 2
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical compound CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 claims 2
- 229950009280 salacetamide Drugs 0.000 claims 2
- RLISWLLILOTWGG-UHFFFAOYSA-N salamidacetic acid Chemical compound NC(=O)C1=CC=CC=C1OCC(O)=O RLISWLLILOTWGG-UHFFFAOYSA-N 0.000 claims 2
- 229950000417 salamidacetic acid Drugs 0.000 claims 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims 2
- 229940120668 salicin Drugs 0.000 claims 2
- 229960000581 salicylamide Drugs 0.000 claims 2
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 claims 2
- 229950001102 salicylsulfuric acid Drugs 0.000 claims 2
- 229960000953 salsalate Drugs 0.000 claims 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims 2
- 229960000894 sulindac Drugs 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- 229960004492 suprofen Drugs 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- 229960002871 tenoxicam Drugs 0.000 claims 2
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 2
- 229960001312 tiaprofenic acid Drugs 0.000 claims 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 2
- 229960005001 ticlopidine Drugs 0.000 claims 2
- PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 claims 2
- 229950010298 tinoridine Drugs 0.000 claims 2
- 229960002905 tolfenamic acid Drugs 0.000 claims 2
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims 2
- 229960001017 tolmetin Drugs 0.000 claims 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 2
- 229950007669 tomoxiprole Drugs 0.000 claims 2
- UCCJWNPWWPJKGL-UHFFFAOYSA-N tropesin Chemical compound CC1=C(CC(=O)OCC(C(O)=O)C=2C=CC=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 UCCJWNPWWPJKGL-UHFFFAOYSA-N 0.000 claims 2
- 229950002470 tropesin Drugs 0.000 claims 2
- IYEPZNKOJZOGJG-UHFFFAOYSA-N xenbucin Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=CC=C1 IYEPZNKOJZOGJG-UHFFFAOYSA-N 0.000 claims 2
- 229950005298 xenbucin Drugs 0.000 claims 2
- 229960004764 zafirlukast Drugs 0.000 claims 2
- 229950004227 zaltoprofen Drugs 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- ZQICGTYUOSVFMN-UHFFFAOYSA-N Iselin Natural products CC1=C(COc2c3ccoc3cc3oc(=O)ccc23)CC(C)(C)CC1 ZQICGTYUOSVFMN-UHFFFAOYSA-N 0.000 claims 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 125000005103 alkyl silyl group Chemical group 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 125000005325 aryloxy aryl group Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229960003803 meclofenamic acid Drugs 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229960004110 olsalazine Drugs 0.000 claims 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960000851 pirprofen Drugs 0.000 claims 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 claims 1
- 229950010302 tiaramide Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj formule I: ,gdjeM predstavlja makrolidnu podjedinicu podstrukture II: ,gdjeR1, R2, R3, R4 i R5 se, međusobno neovisno, bira iz skupine koju čine vodik, C1-C4alkil, alkanoil, alkoksikarbonil, arilmetoksikarbonil, aroil, arilalkil, alkilsilil i alkilsililalkoksialkil; RN predstavlja kovalentnu vezu s X1 u lancu L; L predstavlja lanac podstrukture III: -X1-(CH2)m-Q-(CH2)n-X2- IIIgdjeX1 je -CH2- ili -C(O)-; X2 je -NH- ili -O-;Q je -NH- ili -CH2-;simboli m i n, neovisno, su cijeli brojevi, od 0 do 4; uz uvjet da ako Q = NH, n ne može biti 0; D predstavlja nesteroidnu protuupalnu podjedinicu ili steroidnu podjedinicu, ili njenu farmaceutski prihvatljivu sol ili solvat; gdje"alkil", ukoliko se ne navede drugačije, znači nerazgranati ili razgranati zasićeni jednovalentni ugljikovodični radikal s 1 do 10 atoma ugljika, koji može biti supstituiran s jednim do pet supstituenata, uključujući halogen, hidroksi, alkoksi, acil, acilamino, cijano, amino, N-(C1-C4)alkilamino, N,N-di(C1-C4-alkil)amino, tiokarbonilamino, aciloksi, amidino, alkilamidino, tioamidino, aminoacil, aminokarbonilamino, aminotiokarbonilamino, aminokarboniloksi, aril, heteroaril, ariloksi, ariloksiaril, nitro, karboksil, karboksilalkil, s karboksilom supstituirani alkil, karboksil-cikloalkil, s karboksilom supstituirani cikloalkil, karboksilaril, s karboksilom supstituirani aril, karboksilheteroaril, s karboksilom supstituirani heteroaril, karboksilheterocikl, s karboksilom supstituirani heterocikl, cikloalkil, cikloalkoksi, heteroariloksi, heterocikliloksi, te oksikarbonilamino; ova definicija alkila vrijedi i za druge skupine koje sadrže alkilni ostatak, poput alkoksi ili alkanoila; "cikloalkil" znači prstenasta skupina s 3 do 8 atoma ugljika, s jednim prstenom, izborno kondenziran s arilnom ili heteroarilnom skupinom, te koji može biti supstituiran kao što je specificirano za "aril", niže; "aril" znači nezasićeni aromatski karbociklička skupina s 6 do 14 atoma ugljika, s jednim prstenom ili više kondenziranih prstena, te koja može biti izborno daljnje kondenzirana s alifatskom ili arilnom skupinom, ili može biti supstituirana s jednim ili više supstituenata, koje se bira između halogena, hidroksi, C1-C7alkila, C1-C7alkoksi ili ariloksi, C1-C7 alkiltio ili ariltio, alkilsulfonila, cijano i primarnog ili neprimarnog amino; "heteroaril" znači monociklički ili biciklički aromatski ugljikovodički prsten s 2 do 10 atoma ugljika i od 1 do 4 heteroatoma, poput O, S ili N, te koji može izborno biti kondenziran s drugim heteroarilom, arilom ili alifatskom prstenastom skupinom, te koji može biti supstituiran s istim supstituentima kao što je specificirano za aril, gore; "heterociklički" znači zasićena ili nezasićena skupina, koja s jednim ili više prstena i od 1 do 10 atoma ugljika i od 1 do 4 heteroatoma, koje se bira između dušika, sumpora ili kisika, gdje u kondenziranom prstenastom sustavu jedan ili više drugih prstena može biti aril ili heteroaril, te gdje heterocikl može biti supstituir
Claims (48)
1. Spoj formule I:
[image]
,
gdje
M predstavlja makrolidnu podjedinicu podstrukture II:
[image]
,
gdje
R1, R2, R3, R4 i R5 se, međusobno neovisno, bira iz skupine koju čine vodik, C1-C4alkil, alkanoil, alkoksikarbonil, arilmetoksikarbonil, aroil, arilalkil, alkilsilil i alkilsililalkoksialkil;
RN predstavlja kovalentnu vezu s X1 u lancu L;
L predstavlja lanac podstrukture III:
-X1-(CH2)m-Q-(CH2)n-X2- III
gdje
X1 je -CH2- ili -C(O)-;
X2 je -NH- ili -O-;
Q je -NH- ili -CH2-;
simboli m i n, neovisno, su cijeli brojevi, od 0 do 4;
uz uvjet da ako Q = NH, n ne može biti 0;
D predstavlja nesteroidnu protuupalnu podjedinicu ili steroidnu podjedinicu, ili njenu farmaceutski prihvatljivu sol ili solvat;
gdje
"alkil", ukoliko se ne navede drugačije, znači nerazgranati ili razgranati zasićeni jednovalentni ugljikovodični radikal s 1 do 10 atoma ugljika, koji može biti supstituiran s jednim do pet supstituenata, uključujući halogen, hidroksi, alkoksi, acil, acilamino, cijano, amino, N-(C1-C4)alkilamino, N,N-di(C1-C4-alkil)amino, tiokarbonilamino, aciloksi, amidino, alkilamidino, tioamidino, aminoacil, aminokarbonilamino, aminotiokarbonilamino, aminokarboniloksi, aril, heteroaril, ariloksi, ariloksiaril, nitro, karboksil, karboksilalkil, s karboksilom supstituirani alkil, karboksil-cikloalkil, s karboksilom supstituirani cikloalkil, karboksilaril, s karboksilom supstituirani aril, karboksilheteroaril, s karboksilom supstituirani heteroaril, karboksilheterocikl, s karboksilom supstituirani heterocikl, cikloalkil, cikloalkoksi, heteroariloksi, heterocikliloksi, te oksikarbonilamino; ova definicija alkila vrijedi i za druge skupine koje sadrže alkilni ostatak, poput alkoksi ili alkanoila;
"cikloalkil" znači prstenasta skupina s 3 do 8 atoma ugljika, s jednim prstenom, izborno kondenziran s arilnom ili heteroarilnom skupinom, te koji može biti supstituiran kao što je specificirano za "aril", niže;
"aril" znači nezasićeni aromatski karbociklička skupina s 6 do 14 atoma ugljika, s jednim prstenom ili više kondenziranih prstena, te koja može biti izborno daljnje kondenzirana s alifatskom ili arilnom skupinom, ili može biti supstituirana s jednim ili više supstituenata, koje se bira između halogena, hidroksi, C1-C7alkila, C1-C7alkoksi ili ariloksi, C1-C7 alkiltio ili ariltio, alkilsulfonila, cijano i primarnog ili neprimarnog amino;
"heteroaril" znači monociklički ili biciklički aromatski ugljikovodički prsten s 2 do 10 atoma ugljika i od 1 do 4 heteroatoma, poput O, S ili N, te koji može izborno biti kondenziran s drugim heteroarilom, arilom ili alifatskom prstenastom skupinom, te koji može biti supstituiran s istim supstituentima kao što je specificirano za aril, gore;
"heterociklički" znači zasićena ili nezasićena skupina, koja s jednim ili više prstena i od 1 do 10 atoma ugljika i od 1 do 4 heteroatoma, koje se bira između dušika, sumpora ili kisika, gdje u kondenziranom prstenastom sustavu jedan ili više drugih prstena može biti aril ili heteroaril, te gdje heterocikl može biti supstituiran kao što je specificirano za alkilne skupine, gore.
2. Spoj u skladu s patentnim zahtjevom 1, gdje D je steroid podstrukture IV:
[image]
,
gdje
Ra i Rb se, međusobno neovisno, bira iz skupine koju čine vodik i halogen;
Rf se bira iz skupine koju čine vodik, hidroksilna skupina, halogen, ili tvori karbonilnu skupinu s atomom ugljika na kojeg je vezan;
Rc je kovalentna veza s X2 u lancu L;
Rd i Re se neovisno bira iz skupine koju čine vodik, hidroksi, C1-4alkoksi, ili, zajedno s pripadajućim C-atomima, predstavlja 1,3-dioksolanski prsten, koji može biti daljnje mono- ili disupstituiran s alkilom ili alkenilom;
i
Rj se bira iz skupine koju čine vodik i klor;
gdje
"alkenil" znači nerazgranati ili razgranati jednovalentni ugljikovodični radikal s 2 do 10 atoma ugljika, koji ima najmanje jednu dvostruku vezu ugljik-ugljik, te koji može biti supstituiran s istim skupinama kao alkil.
3. Spoj u skladu s patentnim zahtjevom 2, gdje R1, R2, R3, R4 i R5 se svakog neovisno bira iz skupine koju čine vodik i C1-C4alkil.
4. Spoj u skladu s patentnim zahtjevom 2, gdje R1, R2, R3, R4 i R5 se svakog neovisno bira iz skupine koju čine vodik, metil, etil, propil, iso-propil, butil, sec-butil i tert-butil.
5. Spoj u skladu s patentnim zahtjevom 2, gdje R1, R2, R3, R4 i R5 se neovisno bira iz skupine koju čine vodik i metil.
6. Spoj u skladu s patentnim zahtjevom 2, gdje X1 je CH2, a X2 je NH.
7. Spoj u skladu s patentnim zahtjevom 6, gdje m = 1, n = 1, a Q je CH2.
8. Spoj u skladu s patentnim zahtjevom 2, gdje Rd i Re se neovisno bira iz skupine koju čine vodik, hidroksi, metil, metoksi, etoksi, propoksi, iso-propoksi, butoksi, sec-butoksi, tert-butoksi, ili zajedno s pripadajućim C-atomima predstavlja 1,3-dioksolanski prsten, koji može biti daljnje mono- ili disupstituiran s alkilom ili alkenilom.
9. Spoj u skladu s patentnim zahtjevom 2, gdje podstrukturu IV se bira iz skupine koju čine
[image]
[image]
i
[image]
10. Spoj u skladu s patentnim zahtjevom 2, gdje podstruktura IV je
[image]
11. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
12. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
13. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
14. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
15. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
16. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
17. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
18. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
19. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
20. Spoj u skladu s patentnim zahtjevom 2, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
21. Spoj u skladu s patentnim zahtjevom 1, gdje D je nesteroidna protuupalna podjedinica.
22. Spoj u skladu s patentnim zahtjevom 21, gdje nesteroidnu protuupalnu podjedinicu se bira iz skupine koju čine aceklofenak, acemetacin, acetaminofen, acetaminosalol, acetilsalicilna kiselina, acetilsalicil-2-amino-4-pikolinska kiselina, 5-aminoacetilsalicilna kiselina, alklofenak, aminoprofen, amfenak, ampiron, ampiroksikam, anileridin, bendazak, benoksaprofen, bermoprofen, α-bisabolol, bromfenak, acetat 5-bromsalicilne kiseline, bromosaligenin, bukloksična kiselina, butibufen, karprofen, celekoksib, kromoglikat, cinmetacin, klidanak, klopirak, natrij-diklofenak, diflunisal, ditazol, droksikam, enfenaminska kiselina, etodolak, etofenamat, felbinak, fenbufen, fenklozinska kiselina, fendosal, fenoprofen, fentiazak, fepradinol, flufenak, flufenaminska kiselina, fluniksin, flunoksaprofen, flurbiprofen, glukametacin, glikol-salicilat, ibufenak, ibuprofen, ibuproksam, indometacin, indoprofen, izofezolak, izoksepak, izoksikam, ketoprofen, ketorolak, lornoksikam, loksoprofen, meklofenaminska kiselina, mefenaminska kiselina, meloksikam, mesalamin, metiaziniska kiselina, mofezolak, montelukast, mikofenolna kiselina, nabumeton, naproksen, nifluminska kiselina, nimezulid, oisalazin, oksaceprol, oksaprozin, oksifenbutazon, paracetamol, parsalmid, perisoksal, fenil-acetil-salicilat, fenilbutazon, fenil-salicilat, pirazolak, piroksikam, pirprofen, pranoprofen, protiziniska kiselina, rezerveratol, salacetamid, salicilamid, salicilamid-O-octena kiselina, salicilsumporna kiselina, salicin, salsalat, sulindak, suprofen, suksibuzon, tamoksifen, tenoksikam, teofilin, tiaprofenska kiselina, tiaramid, tiklopidin, tinoridin, tolfenaminska kiselina, tolmetin, tropesin, ksenbucin, ksimoprofen, zaltoprofen, zomepirak, tomoksiprol, zafirlukast i ciklosporin.
23. Spoj u skladu s patentnim zahtjevom 22, gdje nesteroidnu protuupalnu podjedinicu se bira iz skupine koju čine aceklofenak, acemetacin, acetaminofen, acetaminosalol, acetilsalicil-2-amino-4-pikolinska kiselina, 5-aminoacetilsalicilna kiselina, alklofenak, aminoprofen, amfenak, ampiron, ampiroksikam, anileridin, bendazak, benoksaprofen, bermoprofen, α-bisabolol, bromfenak, acetat 5-bromsalicilne kiseline, bromosaligenin, bukloksična kiselina, butibufen, karprofen, celekoksib, kromoglikat, cinmetacin, klidanak, klopirak, natrij-diklofenak, diflunisal, ditazol, droksikam, enfenaminska kiselina, etodolak, etofenamat, felbinak, fenbufen, fenklozinska kiselina, fendosal, fenoprofen, fentiazak, fepradinol, flufenak, flufenaminska kiselina, fluniksin, flunoksaprofen, flurbiprofen, glukametacin, glikol-salicilat, ibufenak, ibuprofen, ibuproksam, indometacin, indoprofen, izofezolak, izoksepak, izoksikam, ketoprofen, ketorolak, lornoksikam, loksoprofen, meklofenaminska kiselina, mefenaminska kiselina, meloksikam, mesalamin, metiaziniska kiselina, mofezolak, montelukast, nabumeton, naproksen, nifluminska kiselina, nimezulid, olsalazin, oksaceprol, oksaprozin, oksifenbutazon, paracetamol, parsalmid, perisoksal, fenil-acetil-salicilat, fenilbutazon, fenil-salicilat, pirazolak, piroksikam, pirprofen, pranoprofen, protiziniska kiselina, rezerveratol, salacetamid, salicilamid, salicilamid-O-octena kiselina, salicilsumporna kiselina, salicin, salsalat, sulindak, suprofen, suksibuzon, tamoksifen, tenoksikam, teofilin, tiaprofenska kiselina, tiaramid, tiklopidin, tinoridin, tolfenaminska kiselina, tolmetin, tropesin, ksenbucin, ksimoprofen, zaltoprofen, zomepirak, tomoksiprol, zafirlukast i ciklosporin.
24. Spoj u skladu s patentnim zahtjevom 22, gdje nesteroidnu protuupalnu podjedinicu se bira iz skupine koju čine indometacin, flufenaminska kiselina, fluniksin i teofilin.
25. Spoj u skladu s patentnim zahtjevom 22, gdje nesteroidna protuupalna podjedinica je indometacin.
26. Spoj u skladu s patentnim zahtjevom 1, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
27. Spoj u skladu s patentnim zahtjevom 1, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
28. Spoj u skladu s patentnim zahtjevom 1, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
29. Spoj u skladu s patentnim zahtjevom 1, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
30. Spoj u skladu s patentnim zahtjevom 1, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
31. Spoj u skladu s patentnim zahtjevom 1, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
32. Spoj u skladu s patentnim zahtjevom 1, sa strukturom
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat.
33. Farmaceutski pripravak, koji sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegovu farmaceutski prihvatljivu sol ili solvat, kao i farmaceutski prihvatljivu podlogu ili razrjeđivač.
34. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time, ili povezana s neželjenim upalnim imunosnim odgovorom i svim bolestima i stanjima induciran ili povezanim s prekomjernim lučenjem TNF-α i IL-1.
35. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
36. Upotreba spoja u skladu s patentnim zahtjevom 35, gdje upalna stanja i imunosne poremećaje se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, kronična opstruktivna plućna bolest, upalna stanja crijeva, Crohnova bolest, bronhitis, te cistična fibroza.
37. Upotreba spoja u skladu s patentnim zahtjevom 35, gdje navedena upalna stanja i imunosne poremećaje se bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože te srca.
38. Upotreba spoja u skladu s patentnim zahtjevom 35, gdje upalna stanja i imunosne poremećaje se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, gihtični artritis, uveitis, konjunktivitis, upalna stanja crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, egzem, dermatitis, infarktno oštećenje koronarnih žila, kronična upala, endotoksinski šok, te poremećaji proliferacije glatkih mišića.
39. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje bolesti, poremećaja i stanja, naznačena time, ili povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
40. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje astme.
41. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje kronične opstruktivne plućne bolesti.
42. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalne bolesti crijeva.
43. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje psorijaze.
44. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegova farmaceutski prihvatljiva sol ili solvat, namijenjen upotrebi u medicinskoj terapiji.
45. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegova farmaceutski prihvatljiva sol ili solvat, namijenjen upotrebi u liječenju astme.
46. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegova farmaceutski prihvatljiva sol ili solvat, namijenjen upotrebi u liječenju kronične opstruktivne plućne bolesti.
47. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegova farmaceutski prihvatljiva sol ili solvat, namijenjen upotrebi u liječenju upalne bolesti crijeva.
48. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegova farmaceutski prihvatljiva sol ili solvat, namijenjen upotrebi u liječenju psorijaze.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
PCT/IB2004/001235 WO2004094449A1 (en) | 2003-04-24 | 2004-04-23 | Macrolide-conjugates with anti-inflammatory activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20090551T1 true HRP20090551T1 (hr) | 2010-01-31 |
Family
ID=33307078
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
HR20090551T HRP20090551T1 (hr) | 2003-04-24 | 2009-10-15 | Makrolidni konjugati s protuupalnom aktivnošću |
HR20110763T HRP20110763T1 (hr) | 2003-04-24 | 2011-10-19 | Makrolidni konjugati s protuupalnom aktivnošću |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110763T HRP20110763T1 (hr) | 2003-04-24 | 2011-10-19 | Makrolidni konjugati s protuupalnom aktivnošću |
Country Status (28)
Country | Link |
---|---|
US (1) | US7579334B2 (hr) |
EP (2) | EP2070940B1 (hr) |
JP (1) | JP4613366B2 (hr) |
KR (1) | KR101107336B1 (hr) |
CN (1) | CN100393741C (hr) |
AR (1) | AR044083A1 (hr) |
AT (1) | ATE518876T1 (hr) |
AU (1) | AU2004232546B2 (hr) |
BR (1) | BRPI0410490A (hr) |
CA (1) | CA2523081C (hr) |
CL (1) | CL2004000872A1 (hr) |
CY (2) | CY1109491T1 (hr) |
DE (1) | DE602004022047D1 (hr) |
DK (2) | DK1633771T3 (hr) |
ES (2) | ES2330109T3 (hr) |
HK (2) | HK1086842A1 (hr) |
HR (3) | HRP20030324A2 (hr) |
IS (2) | IS2736B (hr) |
ME (1) | MEP34708A (hr) |
MX (1) | MXPA05011359A (hr) |
NO (2) | NO333909B1 (hr) |
PL (2) | PL2070940T3 (hr) |
PT (2) | PT1633771E (hr) |
RS (1) | RS52621B (hr) |
RU (1) | RU2355699C2 (hr) |
SI (2) | SI1633771T1 (hr) |
WO (1) | WO2004094449A1 (hr) |
ZA (1) | ZA200508388B (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
EP1723159B1 (en) | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
BRPI0514254A (pt) * | 2004-08-12 | 2008-06-03 | Glaxosmithkline Zagreb | uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal |
US20060183696A1 (en) * | 2004-08-12 | 2006-08-17 | Pliva-Istrazivacki Institut D.O.O. | Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract |
ES2337915T3 (es) | 2004-10-27 | 2010-04-30 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Conjugados con adtividad antiinflamatoria. |
TWI423819B (zh) * | 2005-12-22 | 2014-01-21 | Hydra Biosciences Inc | 用於調節trpa1功能之化合物 |
WO2007093840A2 (en) * | 2006-02-15 | 2007-08-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
EP2262483A2 (en) * | 2008-03-05 | 2010-12-22 | Panacea Biotec Limited | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
CN102838660B (zh) * | 2011-06-23 | 2016-11-02 | 上海市第一人民医院 | 一种抑制炎症免疫反应的小肽及其应用 |
US20140256696A1 (en) | 2013-03-08 | 2014-09-11 | Allergan, Inc. | Steroid conjugates |
WO2014138343A1 (en) * | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Antibiotic conjugates with nonsteroidal anti-inflammatory drugs |
BR112015021836A2 (pt) | 2013-03-08 | 2017-07-18 | Allergan Inc | conjugados de antibióticos diretamente ligados com drogas esteroides |
JP2016510753A (ja) * | 2013-03-08 | 2016-04-11 | アラーガン、インコーポレイテッドAllergan,Incorporated | ステロイド薬と結合した抗生物質共役体 |
WO2016013030A2 (en) | 2014-07-23 | 2016-01-28 | Sphaera Pharma Pvt. Ltd. | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0257956B2 (en) | 1986-08-19 | 2000-11-22 | Genentech, Inc. | Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion |
DE3860503D1 (de) * | 1987-09-03 | 1990-10-04 | Pliva Pharm & Chem Works | 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung. |
SE9100341D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroids |
SE9100342D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
GB9225923D0 (en) | 1992-12-11 | 1993-02-03 | Rhone Poulenc Rorer Ltd | New compositions of matter |
CA2149777C (en) | 1992-12-24 | 2004-05-25 | Michael John Ashton | New steroids |
KR970704455A (ko) | 1994-08-12 | 1997-09-06 | 우에하라 아끼라 | 인터류킨 5 생성 억제제(Interleukin 5 Production Inhibitor) |
WO1996004920A1 (fr) | 1994-08-12 | 1996-02-22 | Taisho Pharmaceutical Co., Ltd. | Inhibiteur de production de l'interleukine-5 |
DE19616573C2 (de) | 1996-04-25 | 1999-03-04 | Pari Gmbh | Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase |
JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
WO2000025776A1 (en) * | 1998-10-30 | 2000-05-11 | Nitromed, Inc. | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
IT1306205B1 (it) | 1999-01-15 | 2001-05-30 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
HRP20000310A2 (en) | 2000-05-17 | 2002-02-28 | Pliva Farmaceutska Ind Dioniko | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
FI110835B (fi) | 2000-07-11 | 2003-03-31 | Radiolinja Ab | Menetelmä palvelunumeropuhelun tarjoamiseksi matkaviestintilaajalle ennalta määrätyllä taksalla |
HRP20010018A2 (en) | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
US20040186063A1 (en) * | 2002-02-15 | 2004-09-23 | Hans-Jurgen Gutke | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
US20050171342A1 (en) * | 2002-02-15 | 2005-08-04 | Michael Burnet | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
EP1483579A4 (en) * | 2002-02-15 | 2006-07-12 | Merckle Gmbh | CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION AND USE OF CONJUGATES, FORMULATION AND PHARMACEUTICAL APPLICATIONS OBTAINED FROM SUCH CONJUGATES |
EP1551865B1 (en) * | 2002-07-08 | 2009-04-22 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Hybrid molecules of macrolides with steroidal/non-steroidal anti-inflammatory molecules |
PL374646A1 (en) | 2002-07-08 | 2005-10-31 | Pliva-Istrazivacki Institutt D.O.O. | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
CA2489402A1 (en) * | 2002-07-08 | 2004-01-15 | Pliva-Istrazivacki Institut D.O.O. | New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
-
2003
- 2003-04-24 HR HR20030324A patent/HRP20030324A2/hr not_active Application Discontinuation
-
2004
- 2004-04-22 US US10/830,858 patent/US7579334B2/en not_active Expired - Fee Related
- 2004-04-23 PL PL09075145T patent/PL2070940T3/pl unknown
- 2004-04-23 AU AU2004232546A patent/AU2004232546B2/en not_active Ceased
- 2004-04-23 CN CNB2004800110487A patent/CN100393741C/zh not_active Expired - Fee Related
- 2004-04-23 CL CL200400872A patent/CL2004000872A1/es unknown
- 2004-04-23 DK DK04729157T patent/DK1633771T3/da active
- 2004-04-23 WO PCT/IB2004/001235 patent/WO2004094449A1/en active Application Filing
- 2004-04-23 PL PL04729157T patent/PL1633771T3/pl unknown
- 2004-04-23 MX MXPA05011359A patent/MXPA05011359A/es active IP Right Grant
- 2004-04-23 RS YU20050873A patent/RS52621B/en unknown
- 2004-04-23 RU RU2005131937/04A patent/RU2355699C2/ru not_active IP Right Cessation
- 2004-04-23 PT PT04729157T patent/PT1633771E/pt unknown
- 2004-04-23 CA CA2523081A patent/CA2523081C/en not_active Expired - Lifetime
- 2004-04-23 SI SI200431253T patent/SI1633771T1/sl unknown
- 2004-04-23 KR KR1020057020252A patent/KR101107336B1/ko not_active IP Right Cessation
- 2004-04-23 PT PT09075145T patent/PT2070940E/pt unknown
- 2004-04-23 ES ES04729157T patent/ES2330109T3/es not_active Expired - Lifetime
- 2004-04-23 SI SI200431768T patent/SI2070940T1/sl unknown
- 2004-04-23 AT AT09075145T patent/ATE518876T1/de active
- 2004-04-23 DK DK09075145.4T patent/DK2070940T3/da active
- 2004-04-23 AR ARP040101400A patent/AR044083A1/es unknown
- 2004-04-23 ME MEP-347/08A patent/MEP34708A/xx unknown
- 2004-04-23 BR BRPI0410490-0A patent/BRPI0410490A/pt not_active Application Discontinuation
- 2004-04-23 EP EP09075145A patent/EP2070940B1/en not_active Expired - Lifetime
- 2004-04-23 EP EP04729157A patent/EP1633771B1/en not_active Expired - Lifetime
- 2004-04-23 ES ES09075145T patent/ES2370371T3/es not_active Expired - Lifetime
- 2004-04-23 DE DE602004022047T patent/DE602004022047D1/de not_active Expired - Lifetime
- 2004-04-23 JP JP2006506511A patent/JP4613366B2/ja not_active Expired - Fee Related
-
2005
- 2005-10-17 ZA ZA200508388A patent/ZA200508388B/xx unknown
- 2005-11-22 IS IS8141A patent/IS2736B/is unknown
- 2005-11-23 NO NO20055535A patent/NO333909B1/no not_active IP Right Cessation
-
2006
- 2006-08-09 HK HK06108841.8A patent/HK1086842A1/xx not_active IP Right Cessation
-
2009
- 2009-07-24 HK HK09106861.4A patent/HK1129681A1/xx not_active IP Right Cessation
- 2009-10-14 CY CY20091101070T patent/CY1109491T1/el unknown
- 2009-10-15 HR HR20090551T patent/HRP20090551T1/hr unknown
-
2010
- 2010-12-29 IS IS8941A patent/IS8941A/is unknown
-
2011
- 2011-10-19 HR HR20110763T patent/HRP20110763T1/hr unknown
- 2011-10-25 CY CY20111101008T patent/CY1111978T1/el unknown
-
2013
- 2013-06-28 NO NO20130898A patent/NO335552B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20090551T1 (hr) | Makrolidni konjugati s protuupalnom aktivnošću | |
JP2008517993A5 (hr) | ||
RU2005103227A (ru) | Новые нестероидные противовоспалительные вещества, составы и способы их применения | |
AU2002316626B2 (en) | Taxol enhancer compounds | |
ES2416711T3 (es) | Compuestos espiro sustituidos como inhibidores de la angiogénesis | |
ES2395141T3 (es) | Compuestos de bis [tio-hidrazida-amida] en combinación con taxol para el tratamiento del cáncer | |
RU2007119577A (ru) | Конъюгаты, обладающие противовоспалительной активностью | |
AU2007244903B2 (en) | Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods | |
JP2017125036A (ja) | アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法 | |
ES2963111T3 (es) | Derivados de 4-(1,3,4-oxadiazol-2-il)piridina-2(1H)-ona como inhibidores de la histona desacetilasa 6 (HDAC6) para el tratamiento de infecciones E.G | |
JP2006524221A5 (hr) | ||
US20100029631A1 (en) | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | |
CN101970399A (zh) | 组蛋白脱乙酰酶抑制剂 | |
Dong et al. | Synthesis of novel pleuromutilin derivatives. Part 1: Preliminary studies of antituberculosis activity | |
Yadav et al. | Synthesis of new chemical entities from paracetamol and NSAIDs with improved pharmacodynamic profile | |
RU2658910C2 (ru) | Производные хромена, замещённые посредством алкоксида, в качестве ингибиторов взаимодействия tcr-nck | |
WO2006015930A1 (en) | Phenol derivatives | |
JP5424187B2 (ja) | アシルアミノフェニル基を有する抗がん剤 | |
JP7184302B2 (ja) | ヒトトレフォイル因子3の阻害に有用な化合物 | |
ES2630068T3 (es) | Derivado de la cumarina | |
JP2012006869A (ja) | ピリミジノン化合物およびその医薬用途 | |
CN110105283A (zh) | 一种塞来昔布衍生物及其制备方法和用途 | |
CN115505021A (zh) | 具有炎症性肠病治疗作用的乌苏酸衍生物及其制备方法和用途 | |
BR112015030533B1 (pt) | Compostos de benzotiofeno, composição farmacêutica e uso terapêutico dos mesmos | |
CN102807514B (zh) | 取代的苯二胺类衍生物及其制备方法和用途 |